"stage iii" trang 3 - tải miễn phí từ tailieunhanh
The ASAMET trial: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients

The ASAMET trial: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients
9    56    1
An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer

An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer
8    80    1
Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer

Genetic and immunological biomarkers predict metastatic disease recurrence in stage III colon cancer
12    42    1
The IGCA staging system is more accurate than AJCC7 system in stratifying survival of patients with gastric cancer in stage III

The IGCA staging system is more accurate than AJCC7 system in stratifying survival of patients with gastric cancer in stage III
6    71    1
Belotecan/cisplatin versus etoposide/ cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: A multi-center randomized phase III trial

Belotecan/cisplatin versus etoposide/ cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: A multi-center randomized phase III trial
9    51    1
A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma

A phase I study of nedaplatin, pemetrexed and thoracic intensity-modulated radiotherapy for inoperable stage III lung adenocarcinoma
8    39    1
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2- negative advanced stage breast cancer - a multicenter, randomized phase III trial

SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2- negative advanced stage breast cancer - a multicenter, randomized phase III trial
8    54    1
Better survival in right-sided versus leftsided stage I - III colon cancer patients

Better survival in right-sided versus leftsided stage I - III colon cancer patients
14    83    1
Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: Breast cancer subtype analyses

Prognostic impact of AJCC response criteria for neoadjuvant chemotherapy in stage II/III breast cancer patients: Breast cancer subtype analyses
10    80    1
Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: A competing risk analysis

Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: A competing risk analysis
8    35    1
Accelerated hypofractionated threedimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: Preliminary results of an early terminated phase II trial

Accelerated hypofractionated threedimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: Preliminary results of an early terminated phase II trial
13    42    1
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: Study protocol of the TRADE-hypo trial

Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: Study protocol of the TRADE-hypo trial
10    43    1
Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocols

Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocols
8    69    1
Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy

Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy
6    30    1
Adjuvant chemotherapy for stage III colon cancer: Relative dose intensity and survival among veterans

Adjuvant chemotherapy for stage III colon cancer: Relative dose intensity and survival among veterans
13    52    1
Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients

Retrospective analysis of the impact of platinum dose reduction and chemotherapy delays on the outcomes of stage III ovarian cancer patients
8    23    1
Radiographic response to neoadjuvant therapy and its impact on scope of surgery and prognosis in stage IIB/III soft tissue sarcomas

Radiographic response to neoadjuvant therapy and its impact on scope of surgery and prognosis in stage IIB/III soft tissue sarcomas
9    52    1
1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer

1p36 deletion is a marker for tumour dissemination in microsatellite stable stage II-III colon cancer
9    50    1
The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)

The CAIRO4 study: The role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer – a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG)
7    58    1
An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort

An explorative analysis of ERCC1-19q13 copy number aberrations in a chemonaive stage III colorectal cancer cohort
10    43    1